After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...
Novavax Inc. closed 62.24% below its 52-week high of $23.86, which the company reached on June 6th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback